Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCIO-469 + bortezomib
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
SCIO-469 (talmapimod) is an orally active, selective inhibitor of p38α mitogen-activated protein kinase (MAPK), which blocks the synthesis of proinflammatory cytokines such as IL-1β, PGE2, VEGF, MIP-1α and TNFα. This inhibition reduces multiple myeloma tumor growth and survival and can help overcome drug resistance[2][7]. Bortezomib is a small molecule proteasome inhibitor that blocks the 26S proteasome in cells, leading to accumulation of proteins within cancer cells and subsequent cell death. It is approved for use in multiple myeloma and mantle cell lymphoma[1]. The combination of SCIO-469 with bortezomib has been studied in relapsed or refractory multiple myeloma patients; clinical trials showed that this combination was well tolerated with some evidence of efficacy[2][5].
- Other names
- talmapimod
02
Targets
PSMB5 (Proteasome subunit beta Type-5)RK (Ribokinase)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on SCIO-469 + bortezomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCIO-469 + bortezomib.